Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

The company provided 2025 guidance for TTR product sales of $1.6 billion to $1.725 billion, representing a 36% growth at the midpoint compared to 2024. This outlook assumes regulatory approval and the ...

BridgeBio beat investor expectations with 1,028 unique prescriptions for ATTR-CM therapy Attruby, setting the company up to ...

Vontobel Holding Ltd. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 75.2% in ...

In the fourth quarter of 2024, BB Biotech shares posted a total return of -2.7% in CHF and -3.5% in EUR. NAV performance improved, rising by 2.7% in CHF and 2.8% in EUR, though it declined by 4.3% in ...

Amvuttra (vutrisiran) is a prescription drug that’s used to treat nerve damage related to a rare genetic condition. Amvuttra is given as an injection under your skin by a healthcare professional.

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...

BridgeBio’s ATTR cardiomyopathy drug, Attruby, achieved promising sales numbers in the weeks after its FDA approval.

Alnylam Pharmaceuticals Inc (ALNY) reports robust financial performance with a 33% revenue growth and outlines strategic ...

Like other drugs, Amvuttra (vutrisiran) can cause side effects, such as difficulty breathing and low vitamin A levels. If you can’t tolerate side effects of Amvuttra, talk with your doctor.

Q4 2024 Earnings Call Transcript February 13, 2025 Alnylam Pharmaceuticals, Inc. misses on earnings expectations. Reported ...